One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer

Positron emission tomography (PET) imaging is a useful method to evaluate in situ estrogen receptor (ER) status for the early diagnosis of breast cancer and optimization of the appropriate treatment strategy. The 18F-labeled estradiol derivative has been successfully used to clinically assess the ER...

Full description

Bibliographic Details
Main Authors: Hongbo Huang, Ke Li, Gaochao Lv, Guiqing Liu, Xueyu Zhao, Qingzhu Liu, Shanshan Wang, Xi Li, Ling Qiu, Jianguo Lin
Format: Article
Language:English
Published: Hindawi-Wiley 2018-01-01
Series:Contrast Media & Molecular Imaging
Online Access:http://dx.doi.org/10.1155/2018/5362329
id doaj-e3c9ed4089ab4416afa7b0f8e947be05
record_format Article
spelling doaj-e3c9ed4089ab4416afa7b0f8e947be052020-11-25T01:14:20ZengHindawi-WileyContrast Media & Molecular Imaging1555-43091555-43172018-01-01201810.1155/2018/53623295362329One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast CancerHongbo Huang0Ke Li1Gaochao Lv2Guiqing Liu3Xueyu Zhao4Qingzhu Liu5Shanshan Wang6Xi Li7Ling Qiu8Jianguo Lin9Key Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaKey Laboratory of Nuclear Medicine of Ministry of Health and Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaPositron emission tomography (PET) imaging is a useful method to evaluate in situ estrogen receptor (ER) status for the early diagnosis of breast cancer and optimization of the appropriate treatment strategy. The 18F-labeled estradiol derivative has been successfully used to clinically assess the ER level of breast cancer. In order to simplify the radiosynthesis process, one-step 18F-19F isotope exchange reaction was employed for the 18F-fluorination of the tracer of [18F]AmBF3-TEG-ES. The radiotracer was obtained with the radiochemical yield (RCY) of ~61% and the radiochemical purity (RCP) of >98% within 40 min. Cell uptake and blocking assays indicated that the tracer could selectively accumulate in the ER-positive human breast cancer cell lines MCF-7 and T47D. In vivo PET imaging on the MCF-7 tumor-bearing mice showed relatively high tumor uptake (1.4~2.3 %D/g) and tumor/muscle uptake ratio (4~6). These results indicated that the tracer is a promising PET imaging agent for ER-positive breast cancers.http://dx.doi.org/10.1155/2018/5362329
collection DOAJ
language English
format Article
sources DOAJ
author Hongbo Huang
Ke Li
Gaochao Lv
Guiqing Liu
Xueyu Zhao
Qingzhu Liu
Shanshan Wang
Xi Li
Ling Qiu
Jianguo Lin
spellingShingle Hongbo Huang
Ke Li
Gaochao Lv
Guiqing Liu
Xueyu Zhao
Qingzhu Liu
Shanshan Wang
Xi Li
Ling Qiu
Jianguo Lin
One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer
Contrast Media & Molecular Imaging
author_facet Hongbo Huang
Ke Li
Gaochao Lv
Guiqing Liu
Xueyu Zhao
Qingzhu Liu
Shanshan Wang
Xi Li
Ling Qiu
Jianguo Lin
author_sort Hongbo Huang
title One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer
title_short One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer
title_full One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer
title_fullStr One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer
title_full_unstemmed One-Step 18F-Labeling of Estradiol Derivative for PET Imaging of Breast Cancer
title_sort one-step 18f-labeling of estradiol derivative for pet imaging of breast cancer
publisher Hindawi-Wiley
series Contrast Media & Molecular Imaging
issn 1555-4309
1555-4317
publishDate 2018-01-01
description Positron emission tomography (PET) imaging is a useful method to evaluate in situ estrogen receptor (ER) status for the early diagnosis of breast cancer and optimization of the appropriate treatment strategy. The 18F-labeled estradiol derivative has been successfully used to clinically assess the ER level of breast cancer. In order to simplify the radiosynthesis process, one-step 18F-19F isotope exchange reaction was employed for the 18F-fluorination of the tracer of [18F]AmBF3-TEG-ES. The radiotracer was obtained with the radiochemical yield (RCY) of ~61% and the radiochemical purity (RCP) of >98% within 40 min. Cell uptake and blocking assays indicated that the tracer could selectively accumulate in the ER-positive human breast cancer cell lines MCF-7 and T47D. In vivo PET imaging on the MCF-7 tumor-bearing mice showed relatively high tumor uptake (1.4~2.3 %D/g) and tumor/muscle uptake ratio (4~6). These results indicated that the tracer is a promising PET imaging agent for ER-positive breast cancers.
url http://dx.doi.org/10.1155/2018/5362329
work_keys_str_mv AT hongbohuang onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer
AT keli onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer
AT gaochaolv onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer
AT guiqingliu onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer
AT xueyuzhao onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer
AT qingzhuliu onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer
AT shanshanwang onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer
AT xili onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer
AT lingqiu onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer
AT jianguolin onestep18flabelingofestradiolderivativeforpetimagingofbreastcancer
_version_ 1725157327881895936